Sage Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Sage Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.08M	Buy	+10,923	New	+$1.88M	0.81%	36

Other funds holding IBB

WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return

Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return

Factory Mutual Insurance Waltham, Massachusetts $10.6B AUM 34.1% 1-Year Est. Return

Cumberland Advisors Sarasota, Florida $284M AUM 27.11% 1-Year Est. Return

Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return

Sage Capital Management's IBB Position: Q2 2026 in Review

Sage Capital Management opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 10,923 shares worth $2.08M. The stake represents 0.81% of the portfolio and ranks #36 among its holdings.

320 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Sage Capital Management held 10,923 shares of iShares Biotechnology ETF worth $2.08M as of Q2 2026.
iShares Biotechnology ETF was a new Sage Capital Management position in Q2 2026.
iShares Biotechnology ETF made up 0.81% of Sage Capital Management's portfolio in Q2 2026, its #36 holding.
320 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Sage Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.